89 related articles for article (PubMed ID: 10740632)
1. [New combination therapies in hematological malignancies].
Takeshita A; Ohno R
Gan To Kagaku Ryoho; 2000 Mar; 27(3):388-94. PubMed ID: 10740632
[TBL] [Abstract][Full Text] [Related]
2. [Hematological malignancies].
Usui N
Gan To Kagaku Ryoho; 2007 Mar; 34(3):358-66. PubMed ID: 17353625
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
Sweetenham J; Hieke K; Kerrigan M; Howard P; Smartt PF; McIntyre AM; Townshend S
Br J Haematol; 1999 Jul; 106(1):47-54. PubMed ID: 10444162
[TBL] [Abstract][Full Text] [Related]
4. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
[TBL] [Abstract][Full Text] [Related]
5. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
[TBL] [Abstract][Full Text] [Related]
6. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
[TBL] [Abstract][Full Text] [Related]
7. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
8. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Czuczman MS
Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Czuczman MS; Fallon A; Mohr A; Stewart C; Bernstein ZP; McCarthy P; Skipper M; Brown K; Miller K; Wentling D; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-López AJ; Bernstein SH
Semin Oncol; 2002 Feb; 29(1 Suppl 2):36-40. PubMed ID: 11842387
[TBL] [Abstract][Full Text] [Related]
10. [The standard treatments for patients with hematological malignancies in Japan].
Ishizawa K
Gan To Kagaku Ryoho; 2007 May; 34(5):709-12. PubMed ID: 17496442
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
12. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH; Connors JM
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Todeschini G; Gelio S; Tecchio C
Ann Oncol; 2004 Mar; 15(3):538-9. PubMed ID: 14998863
[No Abstract] [Full Text] [Related]
16. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
17. [Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma].
Uzuka Y; Saitou Y; Saitou K; Suzuki S; Yamaguchi M
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1085-90. PubMed ID: 17637545
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Bernardi D; Giacalone A; Spina M; Tirelli U
Ann Oncol; 2004 Aug; 15(8):1298. PubMed ID: 15277275
[No Abstract] [Full Text] [Related]
19. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
